New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation… On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation is now available from the Population Approach Group Europe (PAGE) conference in Rome, Italy. The new significant findings revealed that relative drug exposure is much higher in young children, with bioavailability decreasing with age. Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young children. Enhanced understanding of paediatric nasal drug delivery underscores the importance of agespecific considerations in nasal drug delivery. Efficacy of CT001 administration. solidifies the opioid-sparing advantage of the CT001 formulation, making it a safer option for paediatric patients. Jes Trygved, CEO, Cessatech “We are very pleased with the final results and the opportunity to present them at the PAGE conference. The data strongly support our hypothesis that CT001 is highly effective in children relative to its active comparators and will be instrumental in our further development. This is a significant step towards finalizing the clinical program and making CT001 available to hospitals and the children who need approved, easy-toadminister pain relief.” Related articles Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗